Abstract：
BACKGROUND: Obesity, a known independent risk factor for developing malignancy. Additionally, renal transplant recipients (RTR) confer a 2- to 4-fold increased risk of overall malignancies with an excess absolute risk of .7% per year. While transplant recipients are at risk for obesity and malignancy, the effect of bariatric surgery (BS) in the posttransplantation setting is not well known.
OBJECTIVE: Our study primarily evaluated the impact of BS on cancer incidence in RTR with severe obesity in the posttransplantation setting. Weight loss outcomes were analyzed secondarily.
METHODS: University Hospital.
METHODS: A retrospective study using TriNetX database was developed to analyze cancer outcomes in RTR with posttransplantation BS versus RTR without BS from 2000 to 2023. After the exclusion process and propensity matching, both cohorts consisted of 153 patients.
RESULTS: RTR-BS had a significantly lower incidence of overall cancer and transplant-related cancers (P < .05). No significant difference was identified in cutaneous, gastrointestinal, and reproductive cancers. Percent Excess Weight Loss (%EWL) was significantly lower in RTR-only cohort (11.4%) versus RTR-BS cohort (57.8%) at 5 years. Sleeve gastrectomy (SG) patients (73.19%) had significantly higher %EWL than Roux en-Y gastric bypass (RYGB) patients (49.33%) at 3 years. No difference in cancer incidence was noted between SG and RYGB patients.
CONCLUSIONS: Postrenal transplantation BS had a diminishing effect on overall and transplant-related cancer incidence in RTR with severe obesity. Significant weight loss was also demonstrated with post-renal transplantation BS.
OBJECTIVE: Our study primarily evaluated the impact of BS on cancer incidence in RTR with severe obesity in the posttransplantation setting. Weight loss outcomes were analyzed secondarily.
METHODS: University Hospital.
METHODS: A retrospective study using TriNetX database was developed to analyze cancer outcomes in RTR with posttransplantation BS versus RTR without BS from 2000 to 2023. After the exclusion process and propensity matching, both cohorts consisted of 153 patients.
RESULTS: RTR-BS had a significantly lower incidence of overall cancer and transplant-related cancers (P < .05). No significant difference was identified in cutaneous, gastrointestinal, and reproductive cancers. Percent Excess Weight Loss (%EWL) was significantly lower in RTR-only cohort (11.4%) versus RTR-BS cohort (57.8%) at 5 years. Sleeve gastrectomy (SG) patients (73.19%) had significantly higher %EWL than Roux en-Y gastric bypass (RYGB) patients (49.33%) at 3 years. No difference in cancer incidence was noted between SG and RYGB patients.
CONCLUSIONS: Postrenal transplantation BS had a diminishing effect on overall and transplant-related cancer incidence in RTR with severe obesity. Significant weight loss was also demonstrated with post-renal transplantation BS.
摘要：
背景：肥胖，一个已知的发展为恶性肿瘤的独立危险因素。此外,肾移植受者(RTR)患整体恶性肿瘤的风险增加2~4倍,且每年的绝对风险为.7%.虽然移植受者有肥胖和恶性肿瘤的风险，减肥手术（BS）在移植后环境中的效果尚不为人所知。
目的：我们的研究主要评估了BS对移植后严重肥胖的RTR中癌症发病率的影响。其次分析体重减轻结果。
方法：大学医院。
方法：开发了一项使用TriNetX数据库的回顾性研究，以分析2000年至2023年采用移植后BS的RTR与不采用BS的RTR的癌症结局。在排除过程和倾向匹配之后，这两个队列共153例患者.
结果：RTR-BS的总体癌症和移植相关癌症的发病率明显较低（P<0.05）。在皮肤上没有发现显著差异，胃肠,和生殖癌症。5年时，仅RTR队列（11.4％）的超重损失百分比（％EWL）显着低于RTR-BS队列（57.8％）。袖状胃切除术（SG）患者（73.19％）在3年时的EWL百分比明显高于Rouxen-Y胃旁路术（RYGB）患者（49.33％）。SG和RYGB患者之间的癌症发病率没有差异。
结论：在严重肥胖的RTR患者中，肾移植后BS对整体和移植相关癌症发病率有降低的作用。肾移植后BS也显示出明显的体重减轻。
目的：我们的研究主要评估了BS对移植后严重肥胖的RTR中癌症发病率的影响。其次分析体重减轻结果。
方法：大学医院。
方法：开发了一项使用TriNetX数据库的回顾性研究，以分析2000年至2023年采用移植后BS的RTR与不采用BS的RTR的癌症结局。在排除过程和倾向匹配之后，这两个队列共153例患者.
结果：RTR-BS的总体癌症和移植相关癌症的发病率明显较低（P<0.05）。在皮肤上没有发现显著差异，胃肠,和生殖癌症。5年时，仅RTR队列（11.4％）的超重损失百分比（％EWL）显着低于RTR-BS队列（57.8％）。袖状胃切除术（SG）患者（73.19％）在3年时的EWL百分比明显高于Rouxen-Y胃旁路术（RYGB）患者（49.33％）。SG和RYGB患者之间的癌症发病率没有差异。
结论：在严重肥胖的RTR患者中，肾移植后BS对整体和移植相关癌症发病率有降低的作用。肾移植后BS也显示出明显的体重减轻。
